Development · 22 Sep 2026
1 publisher has reported this development. Each act of reporting is below, cited.
Roche's experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial.
A single act of reporting so far, corroborating sources join this record as they publish.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.